News & Resources

Seated group in a dark room listening to a presentation

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting

Read More
Tray of trial lenses
Retinal Physician

Rethinking Retinal Fluid in Neovascular AMD

Read Article
Eye being scanned by a laser

Bioerodible EYP-1901 (vorolanib intravitreal insert): Key Learnings from the Phase…

Read Scientific Publication

In The News

See All
Close up image of human eye
Retinal Physician
August 4, 2026

Rethinking Retinal Fluid in Neovascular AMD
Abstract featured image
The Ophthalmologist
July 30, 2026

EYP-1901 for Retinal Exudative Diseases: Multi-Mechanism of Action and Phase 2 Clinical Trial Highlights
Abstract featured image
The Ophthalmologist
May 29, 2026

EYP-1901 for Retinal Exudative Diseases
Close-up image of human eye
Ophthalmology 360
March 10, 2026

Tyrosine kinase inhibitors in wet age-related macular degeneration: a new era of durability and disease control

Press Releases

See All
Press Release
September 2, 2026

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
Press Release
August 17, 2026

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
Press Release
August 14, 2026

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Scientific Publications

See All

Bioerodible EYP-1901 (vorolanib intravitreal insert): Key Learnings from the Phase 2 DAVIO 2 Clinical Trial in Wet AMD

Women in Ophthalmology Summer Symposium 2026

DAVIO 2 Phase 2 Trial of Bioerodible EYP-1901 (vorolanib intravitreal insert) for Wet AMD: Post Hoc Analysis in Patients who met Phase 3 Criteria

American Society of Retina Specialists (ASRS)